Pamela Layton is the Executive Chairman of the Board of Bioarray. Prior to joining Bioarray, Mrs. Layton was the founder and CEO of Parcell Laboratories and was responsible for taking one of the first pure stem cell products from bench to bedside for use in spinal fusion surgeries. She holds multiple U.S. and European patents for the ELA cell and its therapeutic applications. Prior to founding Parcell Laboratories, she founded TriGuard Group LLC, a security information platform company that in conjunction with a subsidiary of ADT brought a novel internet-based alarm notification platform to market. Mrs. Layton holds the patent for the TriGuard Information Management Network. Prior to founding TriGuard Group, she spent seven years providing creative financing structures to domestic and international companies. Mrs. Layton serves as an advisor to entrepreneurial companies within and outside the U.S., mentors companies through the MIT Mentor Smart program, is a member of SBANE and judge for the SBANE Innovation Awards, and is a member of Launchpad and Sky Ventures.
Marcia Fournier, the founder, CEO and a member of the Board of Directors of BIOARRAY has extensive experience in cellular and molecular biology as applied to the mechanisms of cancer progression. Marcia has demonstrated a record of successful achievements, leadership skills, and motivation to carrying out the company’s first test from inception to commercialization. Marcia came to U.S. as a recipient of a scholarship from the Brazilian government to develop her doctoral thesis at the Dana-Farber Cancer Institute. She continued on with post-doctoral work and developed strategies for the discovery of biomarkers to track circulating tumor cells that involved quantitative RT-PCR and the isolation and enrichment of epithelial cells from peripheral blood mononuclear cells by immunomagnetic selection. During subsequent studies with Dr. Mina Bissell at the Lawrence Berkeley National Lab, Marcia applied 3-dimensional (3D) cell culture models to obtain insights into cancer pathways and identify clinically relevant biomarkers for breast cancer. She subsequently held a position as Principal Scientist at GlaxoSmithKline in the Oncology Center of Excellence for Drug Discovery where she conducted research to develop higher-throughput physiologically-relevant models to accelerate the drug discovery process by identifying novel cancer targets and establishing new approaches for drug screening. Marcia is trained in genetics with a Doctoral Degree from Federal University of Rio de Janeiro.
Michal Preminger is a member of the Board of Directors of BIOARRAY. She has been the Executive Director at the Harvard Medical School site of the Harvard University Office of Technology Development since 2005. Prior to joining Harvard, Dr. Preminger held several senior leadership positions in R&D and Marketing/Business Development in the biotech and hi-tech industries and co-founded a biotech company. Among these roles, Dr. Preminger served as Vice President of Protein Therapeutics at Compugen, and as Director of Marketing and Business Development at Lucent Technologies and Avaya. Dr. Preminger earned an undergraduate degree in Medicine at the Hebrew University School of Medicine. She followed with a Masters Degree and a Ph.D. from the Weizmann Institute of Science, and an MBA from INSEAD in Fontainebleau, France.
Henry Kay is a member of the Board of Directors of BIOARRAY. He is a member of Boston Harbor Angels. He retired from Boston Scientific Corporation (BSC) in 2006, where he was Group Vice President of New Market Development / Strategic Planning, Endosurgery. Prior to joining BSC, Henry was based in the UK for five years as Senior Vice President, Sales and Marketing for Allergan Europe, a global eye care company. He has 35 years of experience in the medical industry in roles which include R&D, International Marketing, Regulatory Affairs, and Strategic Planning for major pharmaceutical companies, including Schering-Plough, American Home Products, Sterling Drug and Allergan.
Pauline Murphy is a member of the Board of Directors of BIOARRAY. She is the Senior Managing Director of Investments at Connecticut Innovations and brings broad experience in financial planning and start-up operations. Pauline is a key participant in the budget and planning processes and is a member of the CI Operations Executive Committee. She joined CI in 2002 as controller. Prior to CI she was a senior financial professional with an early-stage software development company; she launched her career at Ernst & Young, LLP. Pauline’s areas of expertise include: Investment Analysis, Cost Management, Financial Reporting & Controls, Process Reengineering, Business Development, Financial Systems, Business Software Implementations, Corporate Governance, Planning and Budgeting.
Jim La France is a Business Advisor for BIOARRAY. He is currently the Chairman of the Board for Vermillion (VRML) Inc.; a publicly traded bio-informatics company in Austin, Texas focused on women’s gynecologic conditions. He is also currently on the Board of publicly traded High Throughput Genomics (HTGM), a next generation sequencing RNA profiling company in Tucson, Arizona. Previously, Mr. La France was CEO of both Vermillion and Omnyx, a GE Healthcare JV with UPMC. Prior to that, Jim held executive commercial leadership roles at Ventana Medical Systems (acquired by Roche Diagnostics) and Bayer Diagnostics. Mr. La France has broad based management and consulting experience in medical diagnostics: general management, commercial leadership, strategic planning, strategic marketing, sales management, & business development. In addition, his experience includes SEC public company governance, multiple regulatory clearances including PMA, and secondary market financing. Jim has a BA in Economics from the University of Connecticut and an MBA from the University of Notre Dame.
Arthur Pardee is a Scientific Advisor for BIOARRAY. He is presently a Professor Emeritus at Harvard Medical School. Prior to this he was the Chief of the Division of Cell Growth and Regulation at Dana-Farber Cancer Institute for many years. A major focus of his research activities in his laboratory was to identify and characterize clinically useful breast cancer markers by using differential RNA-display technique. Dr. Pardee held several Academic Appointments including Professor of Biological Chemistry and Molecular Pharmacology Harvard Medical School, Boston, MA, American Cancer Society Scholar, and Imperial Cancer Research Fund Laboratories, London, England. Dr. Pardee’s education includes a B.S. from the University of California, Berkeley in 1942, an M.A. from California Institute of Technology in 1943, and a Ph.D. from California Institute of Technology in 1947.
Mina Bissell is a Scientific Advisor for BIOARRAY. She holds the title of Distinguished Scientist at Lawrence Berkeley National Laboratory. Dr. Bissell has held many positions over the years including Milton Fellow, Harvard University, American Cancer Society Fellow, Staff Biochemist Lawrence Berkeley National Laboratory, Faculty UCB, Wellcome Professor, Kettering Institute, University of Cincinnati Medical School, Director Cell & Molecular Biology Div., Director of Life Sciences Division, and Associate Director, Biosciences at LBNL, Faculty in Endocrinology and in Molecular Toxicology at UCB/UCSF, Advisor to the Life Sciences Division Director at LBNL, and Biology Scholars Program at UCB. Dr. Bissell earned a B.A. in Chemistry in 1963 from Radcliffe/Harvard College, in Cambridge, MA and a M.A. in 1965 in Bacteriology and Biochemistry. She received her Ph.D. in Microbiology and Molecular Genetics from Harvard in 1969.
Stephen Blakemore is a Scientific Advisor for BIOARRAY. He is currently a Senior Director for Translational Medicine at Epizyme. Dr. Blakemore’s professional experience also includes Associate Director, Translational Medicine, Millennium: The Takeda Oncology Company. Manager, Oncology Technology Discovery Group, GSK Upper Providence Research Centre, Collegeville, PA, USA, Manager, Disease and Biomarker Transcriptomics (DBT), Genomics and Proteomics (GPS), GSK Upper Providence Research Centre, Collegeville, PA, USA, Investigator, Genomics and Proteomic Sciences, GSK Medicines Research Centre, Stevenage, UK, Senior Research Scientist, Differential Gene Expression (DGE) Group, Genetics at GlaxoWellcome (GW) Medicines Research Centre, Stevenage, UK, and Case Reporting Officer Trainee, UK Home Office Forensic Science Service Laboratory, Birmingham, UK. Dr. Blakemore received his Ph.D. from the University of Dundee, UK in 1996. He earned a BSc in Biochemistry from Royal Holloway and Bedford New College, University of London, UK in 1989.
Richard Anderson is a Scientific Advisor for BIOARRAY. He is the Founder, President and CTO of Symmetric Computing. Symmetric Computing was founded in January 2009 to develop affordable supercomputing technology for bioinformatics, life sciences, engineering simulation, energy management, and financial analysis. Richard also has knowledge and experience in machine learning algorithms and its application to bioinformatics. Richard earned a BS in Computer Science, Physics, Applied Math from the University of Massachusetts in 1995.
Todd Arnold is a Scientific Advisor for BIOARRAY. Dr. Arnold is the Managing Director, Mount Sinai Genetic Testing Laboratory in Connecticut. His team of fourty scientists and bioinformaticians generate and analyze sequencing data enabling researchers and clinicians to gain a better understanding of the biology of cancer and inherited diseases as well as to improve the accuracy of diagnoses, apply the most appropriate therapeutic regimens and achieve optimal patient outcomes. PreviouslyDr. Arnold was the Vice President of Research and Development, at 454 Life Sciences, a Roche Company. Prior to joining 454 he was the Director of Product Development and Applications Support for Healthcare at CUNO, Incorporated, a 3M Company. Dr. Arnold earned his Ph.D. in Molecular Biology and Genetics from the University of Georgia and his B.S. in Biological Sciences from Indiana University, Bloomington.